This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
LGND vs. ALKS: Which Stock Is the Better Value Option?
by Zacks Equity Research
LGND vs. ALKS: Which Stock Is the Better Value Option?
Why Is Ligand (LGND) Up 5.3% Since Last Earnings Report?
by Zacks Equity Research
Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ligand's (LGND) Q3 Earnings Miss Estimates, EPS View Down
by Zacks Equity Research
Ligand (LGND) reports lower-than-expected third-quarter 2019 earnings. It also lowers outlook for 2019 earnings. However, revenues were better than expected.
Ligand Pharmaceuticals (LGND) Q3 Earnings Miss Estimates
by Zacks Equity Research
Ligand (LGND) delivered earnings and revenue surprises of -24.62% and 7.12%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Ligand Pharmaceuticals (LGND) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ligand (LGND) Surges: Stock Moves 6.3% Higher
by Zacks Equity Research
Ligand (LGND) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Why Is Ligand (LGND) Down 0.9% Since Last Earnings Report?
by Zacks Equity Research
Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Retrophin Down on Neurological Disorder Drug Study Failure
by Zacks Equity Research
Retrophin (RTRX) declines as the late-stage study on a rare neurological disorder candidate failed to achieve its main goal.
Ligand (LGND) Stock Down Despite Q2 Earnings & Sales Beat
by Zacks Equity Research
Ligand (LGND) reports better-than-expected second-quarter 2019 results and maintains view for the full year.
Ligand Pharmaceuticals (LGND) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Ligand (LGND) delivered earnings and revenue surprises of 11.48% and 9.16%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Ligand Pharmaceuticals (LGND) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ligand Inks Oncology Drug Discovery Deal With PhoreMost
by Zacks Equity Research
Ligand's (LGND) subsidiary Vernalis enters research agreement with privately-held PhoreMost to design compounds targeting an undisclosed novel oncology target.
Ligand Grants Preclinical Candidate Rights to UK-based Firm
by Zacks Equity Research
Ligand (LGND) grants exclusive worldwide rights to a pre-clinical cancer candidate discovered using Vernalis Design platform to Cumulus Oncology.
AMAG Q1 Loss Wider Than Expected, Revenues Lag Estimates
by Zacks Equity Research
AMAG (AMAG) reports wider-than-expected loss and misses sales estimates in the first quarter of 2019.
Mallinckrodt (MNK) Beats on Q1 Earnings & Sales, Raises View
by Zacks Equity Research
Mallinckrodt (MNK) earnings and sales surpass estimates in the first quarter, which led to an increase in annual guidance.
Mylan's (MYL) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Mylan's (MYL) earnings beat estimates but sales miss the same in the first quarter of 2019.
Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q1
by Zacks Equity Research
Ultragenyx (RARE) reports wider-than-expected loss and misses sales estimates in the first quarter of 2019.
Ligand (LGND) Q1 Earnings & Sales Fall Y/Y, Stock Down
by Zacks Equity Research
Ligand (LGND) first-quarter earnings and sales decrease year over year.
Ligand Pharmaceuticals (LGND) Q1 Earnings Lag Estimates
by Zacks Equity Research
Ligand (LGND) delivered earnings and revenue surprises of -95.92% and 13.51%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Ligand Pharmaceuticals (LGND) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: Catabasis, Ligand, Key, Carbonite and Second Sight
by Zacks Equity Research
Zacks.com featured highlights include: Catabasis, Ligand, Key, Carbonite and Second Sight
Rising P/E an Overlooked Criterion: 5 Top Stocks
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratio.
LGND vs. ILMN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
LGND vs. ILMN: Which Stock Is the Better Value Option?
Zacks.com featured expert Kevin Matras highlights: Sallie Mae, United Continental, Celgene and Ligand Pharmaceuticals
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Sallie Mae, United Continental, Celgene and Ligand Pharmaceuticals
4 High Earnings Yield Stocks to Strengthen Your Portfolio
by Zacks Equity Research
Earnings yield is very effective for finding out undervalued stocks.